文献速递造血干细胞移植与细胞治疗

阿巴西普预防儿童骨髓衰竭无关供者造血细胞移植中的移植物抗宿主病

Abatacept GVHD prophylaxis in unrelated hematopoietic cell transplantation for pediatric bone marrow failure.
PubMed 文献 · Blood Adv · 2023-01-01

这项单臂、单中心1期试验评估了在10例接受减低强度或非清髓预处理的儿童非恶性疾病患者中,将阿巴西普加入标准移植物抗宿主病预防方案(环孢素与吗替麦考酚酯)联合无关供者造血细胞移植的耐受性。9例成功植入,2例死亡均与阿巴西普无关,无患者发生重度急性或慢性移植物抗宿主病,1年时8例已停用全身免疫抑制。4剂阿巴西普被认为可耐受,初步疗效令人鼓舞,免疫相关指标支持其应用。

要点

  • 4剂阿巴西普联合标准预防在儿童非恶性疾病无关供者移植中可耐受。
  • 无患者发生重度急性或慢性移植物抗宿主病,1年时8例停用全身免疫抑制。
  • 免疫重建未受阿巴西普影响,CD4+ T细胞中初始细胞相对效应记忆细胞得以保留。

核心结论

  • 在儿童非恶性疾病患者接受无关供者造血细胞移植后,4剂阿巴西普被认为可耐受,初步疗效令人鼓舞,免疫相关指标支持其应用。

研究设计与样本

  • 单臂、单中心1期试验,纳入10例接受减低强度或非清髓预处理后行无关供者造血细胞移植的儿童非恶性疾病患者。
  • 主要目的是评估在标准移植物抗宿主病预防方案(环孢素与吗替麦考酚酯)中加入阿巴西普的耐受性。
  • 通过流式细胞术纵向评估免疫重建,并与阿巴西普2期试验中的儿童患者进行比较。

主要发现

  • 9例患者成功植入,1例因细胞剂量不足发生原发性移植物排斥,1例合并巨细胞病毒血症发生继发性移植物排斥。
  • 发生2例死亡,均与阿巴西普无关。
  • 1例发生可能的移植后淋巴增殖性疾病,对利妥昔单抗和免疫抑制撤减有反应。
  • 无患者发生重度急性或慢性移植物抗宿主病,1年时8例患者已停用全身免疫抑制。
  • 免疫重建未显示受阿巴西普影响,观察到CD4+ T细胞中初始细胞相对效应记忆细胞得以保留,与阿巴西普2期试验相似。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hematopoietic cell transplantation (HCT) is the only readily available cure for many life-threatening pediatric nonmalignant diseases (NMD), but most patients lack a matched related donor and are at higher risk for graft-versus-host disease (GVHD). Use of abatacept (Aba) to target donor T-cell activation has been safe and effective in preventing GVHD after unrelated donor (URD) HCT for malignant diseases (Aba2 trial). Our primary objective was to evaluate the tolerability of Aba added to standard GVHD prophylaxis (cyclosporine and mycophenolate mofetil) in pediatric patients with NMD undergoing URD HCT. In this single-arm, single-center phase 1 trial, 10 patients receiving reduced intensity or nonmyeloablative conditioning underwent URD HCT. Immune reconstitution was assessed longitudinally via flow cytometry and compared to pediatric patients on Aba2. Nine patients successfully engrafted, with 1 primary graft rejection in the setting of inadequate cell dose; secondary graft rejection occurred in 1 patient with concurrent cytomegalovirus viremia. Two deaths occurred, both unrelated to Aba. One patient developed probable posttransplant lymphoproliferative disease, responsive to rituximab and immune suppression withdrawal. No patients developed severe acute or chronic GVHD, and 8 patients were off systemic immunosuppression at 1 year. Immune reconstitution did not appear to be impacted by Aba, and preservation of naïve relative to effector memory CD4+ T cells was seen akin to Aba2. Thus, 4 doses of Aba were deemed tolerable in pediatric patients with NMD following URD HCT, with encouraging preliminary efficacy and supportive immune correlatives in this NMD cohort.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Stenger EO, Watkins B, Rogowski K, et al. Abatacept GVHD prophylaxis in unrelated hematopoietic cell transplantation for pediatric bone marrow failure. Blood Adv. 2023. PMID: 36724508. doi:10.1182/bloodadvances.2022008545

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。